ClinicalTrials.gg
CompletedNCT00122330Updated Dec 4, 2006

Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

A Phase 3 interventional study of eculizumab in Hemoglobinuria, Paroxysmal, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 43 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2006-12-04.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Educational/counseling/training

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal — none open to participants now, none under way, none of them phase 3. eculizumab · Hemoglobinuria, Paroxysmal.

Enrollment
5th of 18
75 · median 37
Started
2004
with 2 others
Phase 3
14 of 18
none open now
Registered
2nd of 18
by date
Lead sponsor
8 of 18
Alexion Pharmaceuticals, Inc.

Among the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal, this one is the 5th largest by enrollment, is one of 3 that started in 2004, is one of 14 in phase 3, and was the 2nd registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

None of the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal is open now. The open studies under Hemoglobinuria, Paroxysmal, anywhere →

About eculizumab

eculizumab: first FDA approval 2007 (SOLIRIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal as a file.
02

Study summary

The primary objective is to evaluate the safety and efficacy of eculizumab in transfusion dependent patients with hemolytic PNH.

03

Conditions studied

  • Hemoglobinuria, Paroxysmal
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have required at least 4 transfusions in the past 12 months
  • PNH type III red blood cell (RBC) clone by flow cytometry of >10%
  • Lactate dehydrogenase (LDH) level > 1.5 x
  • count > 100,000/mm3
  • Patient taking erythropoietin must be on a stable dose for at least 26 weeks
  • Patient taking must be on a stable dose for at least 26 weeks
  • Patient taking must be on a stable dose for at least 4 weeks
  • Patient taking coumadin must be at a stable for at least 4 weeks
  • Patient taking iron supplements or folic acid must be on a stable dose for 4 weeks
  • Willing and able to give written
  • Must avoid conception

Exclusion criteria

Exclusion Criteria:

  • Mean level prior to transfusion over the previous 12 months is >10.5 gm/dl
  • \<500/ul
  • Active bacterial infection
  • Hereditary complement deficiency
  • Participation in any other drug trial or exposure to other investigational agent, device, or procedures within 30 days
  • Pregnant, breast-feeding, or intending to conceive
  • History of meningococcal disease
  • History of bone marrow transplantation
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Educational/counseling/training
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
75 participants

Interventions

06

Study locations

43 sites
  • City of Hope National Medical Center, Div. of Hematology & Bone Marrow Transplant
    Duarte, California 91010-3000, United States
  • University of California at Los Angeles
    Los Angeles, California 90024, United States
  • Scripps Cancer Center
    San Diego, California 92121, United States
  • Stanford University Medical Center, Division of Hematology
    Stanford, California 94305-5821, United States
  • Hartford Hospital, Cancer Clinical Research Office
    Hartford, Connecticut 06102, United States
  • Cleveland Clinic, Dept. of Clinical Research
    Weston, Florida 33331, United States
  • Indiana University Cancer Pavilion, Div. of Hematology-Oncology, Hematological Malignancy Program/Immunology
    Indianapolis, Indiana 46202, United States
  • Johns Hopkins University Medical Center
    Baltimore, Maryland 21205, United States
  • National Heart, Blood, and Lung Institute, National Institutes of Health
    Bethesda, Maryland 20892, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Washington University School of Medicine, Dept. of Internal Medicine/Division of Hematology
    St. Louis, Missouri 63110-1093, United States
  • NYU Clinical Cancer Center
    New York, New York 10016, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10021, United States
  • Duke University Health System, Division of Cell Therapy, Heme Malignancies Program
    Durham, North Carolina 27710, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Presbyterian Medical Center, PENN Comprehensive Hemophilia & Thrombosis Program
    Philadelphia, Pennsylvania 19104, United States
  • Princess Alexandra Hospital, Oncology Haematology Radiation Department
    Woolloongabba, Queensland 4102, Australia
  • Queen Elizabeth Hospital, Dept. of Haematology
    Woodville South, South Australia 5011, Australia
  • Royal Melbourne Hospital, Dept. of Clinical Haematology & Medical Oncology
    Parkville, Victoria 3050, Australia
  • The Royal Perth Hosptial, Department of Haematology/Level 2
    Perth, Western Australia 6000, Australia
  • Ucl St. Luc, Hematology Department
    Brussels, 1200, Belgium
  • University of Alberta, Cross Cancer Institute
    Edmonton, Alberta T6G 2B7, Canada
  • Hospital De L'Hotel Dieu, Hematologie et Oncologie Medicale
    Cedex, Paris 04 75181, France
  • Hopital Saint-Louis, Centre G. Hayem-Secteur Bleu Porte 7, Laboratoire De Pathologie/Greffe de Moelle
    Cedex, Paris 10 75475, France
  • Universitatsklinikum Essen, Zentrum fur Innere Medizin
    Essen, D-45147, Germany
  • Universitatsklinik Greifswald, Innere Medizin C - Hamato-Onkologie
    Greifswald, D-17487, Germany
  • Medizinische Hochschule Hannover, Abt. Hamatologie/Onkologie, Zentrum fur Innere Medizin
    Hannover, D-30625, Germany
  • Saarland University Medical School, Internal Medicine 1
    Homburg/Saar, D-66421, Germany
  • Institut fur Klinische Transfusionmedizin und Immungenetik, Abtlg. Transfusionsmedizin des Universitatskinikums Ulm
    Ulm, D-89081, Germany
  • St. James Hospital, Haematology Department
    Dublin, 8, Ireland
  • Azienda Ospedaliera Universitaria Careggi, Dipartimento di area critica medico-chirurgica
    Firenze, 50139, Italy
  • Ospedale San Martino, Dept. of Hematology
    Genova, I-16132, Italy
  • Ospedale Maggiore di Milano, Divisione di Ematologia
    Milano, 35-20122, Italy
  • Universitar degli Studi di Napoli, Divisione di Ematologia, Azienda Universitar Policlinico
    Napoli, 5-80131, Italy
  • Ospedale San Bortolo, Divisione di Ematologia
    Vicenza, 37-36100, Italy
  • UMC St. Radboud, Dept. of Hematology
    Nijmegen, GA 6525, Netherlands
  • Lund University Hospital, Department of Internal Medicine, Section of Hematology
    Lund, SE-22185, Sweden
  • Umea University Hospital, Dept. of Internal Medicine 3, Section for Hematology
    Umea, 90185, Sweden
  • Universitatsklinik Basel, Division of Hematology
    Basel, CH 4031, Switzerland
  • Royal Cornwall Hospital, Haematology Dept.
    Truro, Cornwall TR1 3LJ, United Kingdom
  • Belfast City Hospital, Dept. of Haematology C Floor
    Belfast, BT9 7AB, United Kingdom
  • Leeds General Infirmary, D Floor Brotherton Wing
    Leeds, LS1 3EX, United Kingdom
  • St. George's Hospital, Department of Haematology
    London, SW17 OQT, United Kingdom
07

References and documents

Publications

  • Hillmen P, Young NS, Schubert J, Brodsky RA, Socie G, Muus P, Roth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006 Sep 21;355(12):1233-43. doi: 10.1056/NEJMoa061648. PubMed 16990386 ↗
  • Hill A, Rother RP, Wang X, Morris SM Jr, Quinn-Senger K, Kelly R, Richards SJ, Bessler M, Bell L, Hillmen P, Gladwin MT. Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2010 May;149(3):414-25. doi: 10.1111/j.1365-2141.2010.08096.x. Epub 2010 Mar 8. PubMed 20230403 ↗
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2004 and a completion of Jan 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2005
First posted
Jul 22, 2005
Start
Oct 2004
Completion
Jan 2006
Last update
Dec 4, 2006
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Dec 4, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00122330
First posted
Jul 22, 2005
Start date
Oct 2004
Completion
Jan 2006
Last update
Dec 4, 2006
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eculizumab

Start the discussion